Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 1 asset: 1 approved | Approved assets only | 15 Aug 2029Difelikefalin · Phase 2 | — | — | — | — | |
MC2 TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 2 | MC2-25Phase 2 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
MedicePrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Mediforum Ltd., Co.Private | 1 asset: 1 Ph 3 | PM012Phase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
| 2 assets: 2 Ph 3 | Beruzatatug pelitecanPhase 3 · Non-Small Cell Lung Cancer | Nov 2026Beruzatatug pelitecan · Phase 2 | — | — | — | — | |
MedImmune LLCPrivate | 5 assets: 3 approved, 2 Ph 3 | MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal | 30 Nov 2026Tremelimumab · Phase 2 | — | — | — | — |
Medison PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
MedixPrivate | 1 asset: 1 Ph 3 | TesofensinePhase 3 · ObesityReliable signal | None on record | — | — | — | — |
Medunik USAPrivate | 1 asset: 1 approved | Approved assets only | Feb 2028Hydroxyurea (Siklos) · Phase 2 | — | — | — | — |
Meiji Seika PharmaPrivate | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 26 Jan 2027Belumosudil · Phase 1 | — | — | — | — |
Meitheal PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Memgen, Inc.Private | 1 asset: 1 Ph 1 | MEM-288Phase 1 · Non-Small Cell Lung Cancer | Feb 2027MEM-288 · Phase 1 | — | — | — | — |
Meridigen BiotechPrivate | 1 asset: 1 Ph 2 | SolizmestrocelPhase 2 · Chronic Obstructive Pulmonary DiseaseWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | TML-6Phase 2 · Alzheimer's DiseaseWeak signal | 30 Apr 2028TML-6 · Phase 2 | — | — | — | — | |
Merus N.V.Private | 2 assets: 1 approved, 1 Ph 2 | PamvatamigPhase 2 · Non-Small Cell Lung Cancer | 31 Dec 2026Zenocutuzumab · Phase 2 | — | $367MSep 2025 | Ended Sep 2026 | $328M |
MeryxPrivate | 1 asset: 1 Ph 2 | MRX-2843Phase 1/2 · Acute Myeloid LeukemiaWeak signal | None on record | — | — | — | — |
Merz PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | IncobotulinumtoxinA (Xeomin)Phase 3 · Parkinson's Disease | None on record | — | — | — | — |
Merz TherapeuticsPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
MicrobioticaPrivate | 1 asset: 1 Ph 1 | MB310Phase 1 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
Midas Pharma GmbHPrivate | 1 asset: 1 other | Ranibizumab (Ranivisio)Age-Related Macular Degeneration | None on record | — | — | — | — |
MindRank AIPrivate | 1 asset: 1 Ph 3 | MDR-001Phase 3 · Obesity | Jun 2027MDR-001 · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 2 | MS-553Phase 1/2 · Chronic Lymphocytic Leukemia | Sep 2028MS-553 · Phase 1/2 | — | — | — | — | |
Mirador TherapeuticsPrivate | 2 assets: 2 Ph 2 | MT-201Phase 2 · Ulcerative Colitis | 30 Apr 2027MT-501 · Phase 2 | — | — | — | — |
Mission TherapeuticsPrivate | 1 asset: 1 Ph 1 | MTX325Phase 1 · Parkinson's Disease | 30 Jun 2027MTX325 · Phase 1 | — | — | — | — |
MODAG GmbHPrivate | 1 asset: 1 Ph 1 | EmrusolminPhase 1 · Parkinson's DiseasePartial signal | 15 Jan 2027Emrusolmin · Phase 1 | — | — | — | — |
Moleac Pte LtdPrivate | 1 asset: 1 Ph 3 | MLC901Phase 3 · Alzheimer's Disease | Feb 2029MLC901 · Phase 3 | — | — | — | — |
Mthera Pharma Co., Ltd.Private | 1 asset: 1 Ph 2 | MT101-5Phase 2 · Parkinson's DiseasePartial signal | Jan 2028MT101-5 · Phase 2 | — | — | — | — |
MTI Biotech Inc.Private | 1 asset: 1 Ph 2 | 2-hydroxybenzylamine acetatePhase 1/2 · Alzheimer's Disease | 30 Dec 20282-hydroxybenzylamine acetate · Phase 1/2 | — | — | — | — |
Multitude Therapeutics Inc.Private | 1 asset: 1 Ph 3 | AMT-116Phase 2/3 · Non-Small Cell Lung Cancer | 30 Dec 2026AMT-116 · Phase 1 | — | — | — | — |
Nammi Therapeutics IncPrivate | 1 asset: 1 Ph 1 | QXL138AMPhase 1 · Multiple Myeloma | 31 Dec 2027QXL138AM · Phase 1 | — | — | — | — |
Nanjing Immunophage BiotechPrivate | 1 asset: 1 Ph 2 | IPG11406Phase 2 · Ulcerative ColitisWeak signal | 20 Nov 2028IPG11406 · Phase 2 | — | — | — | — |
Nanjing RegeneCore BiotechPrivate | 1 asset: 1 Ph 2 | RC1416Phase 2 · Chronic Obstructive Pulmonary Disease | 25 Oct 2027RC1416 · Phase 2 | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 1 | Rilertinib (SH-1028)Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026SH009 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 3 | NNG-DEPOPhase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — | |
Napo PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 | — | — | — | — |
NavigenPrivate | 1 asset: 1 Ph 1 | CPT31Phase 1 · HIVWeak signal | None on record | — | — | — | — |
nChroma Bio, Inc.Private | 1 asset: 1 Ph 2 | CRMA-1001Phase 1/2 · Chronic Hepatitis B | Feb 2031CRMA-1001 · Phase 1/2 | — | — | — | — |
ND Partners, LLCPrivate | 1 asset: 1 approved | Approved assets only | Jan 2028Taurolidine/heparin · Phase 3 | — | — | — | — |
NeoImmuneTechPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
NeoTX Therapeutics Ltd.Private | 1 asset: 1 Ph 2 | Naptumomab estafenatoxPhase 2 · Non-Small Cell Lung CancerWeak signal | 1 Mar 2027Naptumomab estafenatox · Phase 1 | — | — | — | — |
Nerviano Medical SciencesPrivate | 1 asset: 1 Ph 1 | NMS-03597812Phase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | atamparibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2028atamparib · Phase 1/2 | — | — | — | — | |
Nested Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | NST-628Phase 1 · Non-Small Cell Lung Cancer | Nov 2028NST-628 · Phase 1 | — | — | — | — |
Nestle Health SciencePrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
NeuraxpharmPrivate | 1 asset: 1 approved | Approved assets only | 21 Jan 2027Ublituximab · Phase 3 | — | — | — | — |
Neurelis, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Neurim Pharmaceuticals Ltd.Private | 1 asset: 1 Ph 3 | Melatonin prolonged-releasePhase 3 | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | TraneurocinPhase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — | |
NEUROBiOGENPrivate | 1 asset: 1 Ph 2 | TisolagilinePhase 2 · Obesity | 31 Jan 2027Tisolagiline · Phase 2 | — | — | — | — |
NeuroDerm Ltd.Private | 1 asset: 1 Ph 3 | Levodopa/carbidopa (ND0612)Phase 3 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
NeuroGen PharmaPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
NeurolixisPrivate | 1 asset: 1 Ph 2 | BefiradolPhase 2 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
Neuron23Private | 1 asset: 1 Ph 2 | NEU-411Phase 2 · Parkinson's Disease | Dec 2027NEU-411 · Phase 2 | — | — | — | — |
Neuronascent, Inc.Private | 1 asset: 1 Ph 1 | NNI-362Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
NeuroPro Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | NPT2042Phase 2 · EpilepsyPartial signal | None on record | — | — | — | — |
Neurosterix Pharma SàrlPrivate | 1 asset: 1 Ph 1 | NTX-253Phase 1 · Schizophrenia | None on record | — | — | — | — |
NeuroTherapia, Inc.Private | 1 asset: 1 Ph 2 | NTRX-07Phase 2 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Newave Pharmaceutical IncPrivate | 1 asset: 1 Ph 1 | NexatoclaxPhase 1 · Acute Myeloid Leukemia | 31 Dec 2026Nexatoclax · Phase 1 | — | — | — | — |
Newleos TherapeuticsPrivate | 1 asset: 1 Ph 2 | BasmisanilPhase 2 | 1 May 2029Basmisanil · Phase 2 | — | — | — | — |
Newsoara BiopharmaPrivate | 3 assets: 1 approved, 1 Ph 3, 1 Ph 1 | Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal | 1 Dec 2026HY1272 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 3 | Olvimulogene nanivacirepvecPhase 3 · Ovarian Cancer | Dec 2026Olvimulogene nanivacirepvec · Phase 3 | — | — | — | — | |
NGM BiopharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NGM707Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | $61MDec 2023 | Ended Feb 2024 | $118M |
Nicoya TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | Oct 2027Extended-release calcifediol · Phase 2 | — | — | — | — |
NiKang Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | NKT5097Phase 1 · HR+/HER2- Metastatic Breast Cancer | 31 Jul 2027NKT5097 · Phase 1 | — | — | — | — |
Nimbus Saturn, Inc.Private | 1 asset: 1 Ph 2 | NDI-101150Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
NImmune BiopharmaPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | omilancorPhase 2 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | WD-890Phase 3 · Psoriasis | 30 Nov 2026WD-890 · Phase 3 | — | — | — | — | |
NizhpharmPrivate | 1 asset: 1 Ph 3 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 31 May 2028Chidamide · Phase 3 | — | — | — | — |
Nordic Group B.V.Private | 1 asset: 1 Ph 3 | S-1Phase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
NorginePrivate | 1 asset: 1 Ph 3 | Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis Delta | Dec 2026Tobevibart (VIR-3434) · Phase 3 | — | — | — | — |
Normunity AccelCo, Inc.Private | 1 asset: 1 Ph 1 | NRM-823Phase 1 · Non-Small Cell Lung Cancer | 30 May 2027NRM-823 · Phase 1 | — | — | — | — |
NorthSea Therapeutics B.V.Private | 1 asset: 1 Ph 2 | SEFA-1024Phase 2 · Severe HypertriglyceridemiaPartial signal | None on record | — | — | — | — |
Nova Laboratories LimitedPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
NovaliqPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | Nispomeben (NRD135S.E1)Phase 2 · Diabetic Peripheral Neuropathic PainPartial signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | KQ-2003Phase 1/2 · Multiple MyelomaWeak signal | 31 Dec 2027KQ-2003 · Phase 1 | — | — | — | — | |
NSC-TherapeuticsPrivate | 1 asset: 1 Ph 2 | NSC001Phase 1/2 · Alzheimer's Disease | None on record | — | — | — | — |
Nuance PharmaPrivate | 1 asset: 1 approved | Approved assets only | 1 Mar 2027ensifentrine · Phase 2 | — | — | — | — |
Nuravax, Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | AV-1959RPhase 2 · Alzheimer's DiseaseWeak signal | 1 Apr 2027DUVAX · Phase 1 | — | — | — | — |
NurrOn PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | ATH-399A (HL192)Phase 1 · Parkinson's Disease | None on record | — | — | — | — |
Nuvalent, Inc.Private | 3 assets: 1 approved, 1 Ph 3, 1 Ph 1 | neladalkibPhase 3 · Non-Small Cell Lung Cancer | Jan 2027NVL-330 · Phase 1 | — | $1.3BMar 2026 | ~16.5 qtrs | $316M |
| 2 assets: 1 Ph 2, 1 Ph 1 | NCR201Phase 2 · Parkinson's Disease | Oct 2028NCR201 · Phase 1 | — | — | — | — | |
Odyssey TherapeuticsPrivate | 1 asset: 1 Ph 2 | OD-07656Phase 2 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Oils4CurePrivate | 1 asset: 1 Ph 3 | YCJ-01Phase 3 · Epilepsy | None on record | — | — | — | — |
Oligomerix, IncPrivate | 1 asset: 1 Ph 1 | OLX-07010Phase 1 · Alzheimer's Disease | None on record | — | — | — | — |
Onchilles Pharma IncPrivate | 1 asset: 1 Ph 2 | N17350Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2028N17350 · Phase 1/2 | — | — | — | — |
OncoC4, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 1 | GotistobartPhase 3 · Non-Small Cell Lung Cancer | 30 Nov 2026Gotistobart · Phase 1/2 | — | — | — | — |
OncoPep, Inc.Private | 1 asset: 1 Ph 1 | PVX-410Phase 1 · Multiple MyelomaWeak signal | None on record | — | — | — | — |
OncoResponse, Inc.Private | 1 asset: 1 Ph 2 | OR502Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
OncoVerity, Inc.Private | 1 asset: 1 Ph 2 | CusatuzumabPhase 2 · Acute Myeloid LeukemiaWeak signal | Jan 2027Cusatuzumab · Phase 2 | — | — | — | — |
One-carbon Therapeutics ABPrivate | 1 asset: 1 Ph 2 | TH9619Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026TH9619 · Phase 1/2 | — | — | — | — |
Opna Bio LLCPrivate | 1 asset: 1 Ph 1 | OPN-6602Phase 1 · Multiple Myeloma | Dec 2027OPN-6602 · Phase 1 | — | — | — | — |
OptiNose, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Orano Med Theranostics, SASPrivate | 1 asset: 1 Ph 1 | Pb-DOTAM-GRPR1Phase 1 · Non-Small Cell Lung Cancer | Jan 2027Pb-DOTAM-GRPR1 · Phase 1 | — | — | — | — |
Orca Biosystems, Inc.Private | 2 assets: 1 approved, 1 Ph 2 | OrcaGraft (Orca-Q)Phase 1/2 · Acute Myeloid Leukemia | Nov 2027Orca-T · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | OriCAR-017Phase 1/2 · Multiple Myeloma | 30 Nov 2026OriCAR-017 · Phase 1/2 | — | — | — | — | |
OrsoBioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | TLC-2716Phase 2 · Hypertriglyceridemia | None on record | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
Oxford Vacmedix UK Ltd.Private | 1 asset: 1 Ph 1 | OVM-200Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Pacylex PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | ZelenirstatPhase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.